Impact of systemic inflammatory markers in patients with ALK-positive non-small cell lung cancer treated with crizotinib
Küçük Resim Yok
Tarih
2023
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Elsevier Espana S.L.U
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Objectives: To evaluate the prognostic utility of inflammation-based prognostic scores in patients with ALK-positive metastatic or non-resectable non-small-cell lung cancer (NSCLC) treated with crizotinib. Patients and Methods: A total of 82 patients with ALK-positive metastatic or non-resectable NSCLC who received ALK TKI crizotinib were included. Pre-treatment modified Glasgow prognostic score (mGPS), prognostic nutritional index (PNI), and systemic immune-inflammation index (SII) were calculated. Multivariable logistic regression and Cox proportional hazards models were used to assess the impact of pretreatment mGPS, PNI, and SII on overall survival (OS), progression-free survival (PFS), and objective response rate (ORR). Results: The ORR was 77.2%, while 1-year OS and PFS rates were 95.0% and 93.5%, respectively. The univariate analysis revealed significantly higher 1-year PFS (89.4 vs. 64.4%, p=0.043) and OS (92.0 vs. 83.3%, p=0.01) rates in patients with low (<934.7) vs. high (?934.7) SII scores. Multivariate analysis revealed that PNI ?0.09 was a significant determinant of poorer 1-year OS rates (hazard ratio [HR]: 2.46, 95% confidence interval [CI] 0.88–4.85, p=0.035). No significant difference was observed in survival rates according to gender, age, smoking status, prior lines of therapy, or mGPS scores, while higher mGPS scores (odds ratio [OR]: 0.1, 95%CI 0.16–1.04; p=0.009) and higher PNI scores (OR: 0.16, 95% CI 0.02–0.55; p=0.035) were associated with poorer ORR. Conclusion: Our findings indicate the prognostic significance of PNI and SII in terms of survival outcome and the impact of mGPS and PNI on treatment response in patients with ALK-positive NSCLC treated with crizotinib. © 2022 Sociedade Portuguesa de Pneumologia
Açıklama
Anahtar Kelimeler
ALK-positive, Inflammation-based prognostic scores, NSCLC, Survival, Treatment response, albumin, C reactive protein, crizotinib, hemoglobin, adrenal metastasis, adult, aged, ALK positive non small cell lung cancer, ALK positive non small cell lung cancer, Article, assessment of humans, bone metastasis, brain metastasis, cancer prognosis, cancer staging, cohort analysis, computer assisted tomography, controlled study, diagnostic test accuracy study, distant metastasis, ECOG Performance Status, female, follow up, human, hypoalbuminemia, inflammation based prognostic score, leukocyte count, liver metastasis, lung metastasis, lymph node metastasis, lymphocyte count, major clinical study, male, metastasis, modified Glasgow prognostic score, multicenter study, neutrophil count, non small cell lung cancer, nuclear magnetic resonance imaging, overall response rate, overall survival, people by smoking status, platelet count, prognostic assessment, prognostic nutritional index, progression free survival, receiver operating characteristic, response evaluation criteria in solid tumors, retrospective study, sensitivity and specificity, survival rate, systemic immune inflammation index, treatment response
Kaynak
Pulmonology
WoS Q Değeri
Scopus Q Değeri
Q1
Cilt
29
Sayı
6
